Years before any symptom or suspicion, a man's blood may already carry quiet signals about the prostate cancer that could someday come for him. Researchers at the Oxford Population Health Centre, working with stored samples from a large European cohort, have identified seven proteins whose levels track with the later emergence of aggressive disease. The discovery offers a glimpse of a future in which the body's own chemistry is read as an early record, though the signals remain faint and far from the clinic.
Seven Blood Proteins Linked to Aggressive Prostate Cancer, but Not Yet Ready for Clinical Testing
Blood drawn years ago carries hints about the cancer a man might later develop
Mark
So what's actually new here? Blood tests for prostate cancer already exist.
Mimi
What's new is the timing and the breadth. They measured over 6,000 proteins in blood collected well before diagnosis, and found seven linked to aggressive disease.
Luke
Linked is the key word. These are associations, not predictions of who will get sick.
Mark
The GZMK finding sounds interesting. It's an immune protein.
Mimi
Yes, it's made by immune cells that help destroy abnormal cells. Twelve proteins were tied to cancers diagnosed more than 15 years after sampling, and GZMK was among them.
Luke
The immune-containment idea is the authors' reading. The study doesn't show that mechanism directly, so I'd hold it loosely.
Mark
And ANKRD1?
Mimi
It was consistently associated with several severe forms, including metastatic or fatal cases.
Luke
Worth noting the authors say the ERBB3, KRAS and NRAS links don't mean cancer was already there at sampling. We don't know yet what the proteins are doing.
Mark
So could a doctor use any of this now?
Mimi
No. Most associations were moderate, and nobody has shown yet that they improve risk assessment for significant cancer.
Luke
Right. Until that's tested, this is a list of leads, not a test.
Le Pouls
- Stored blood from men sampled long before diagnosis is now being read for signs of aggressive prostate cancer to come.
- Among more than 6,000 proteins measured, seven stand out as linked to severe forms of the disease.
- ANKRD1 appears consistently across several dangerous variants, including metastatic and fatal cases.
- Associations with proteins from ERBB3, KRAS and NRAS point toward disease roughly a decade after sampling, though researchers stress this does not prove cancer was already present.
- The associations are mostly moderate, and no one yet knows whether these markers would improve risk assessment, so clinical testing remains a distant prospect.
Years before any symptom or suspicion, a man's blood may already carry quiet signals about the prostate cancer that could someday come for him. Researchers at the Oxford Population Health Centre, working with stored samples from a large European cohort, have identified seven proteins whose levels track with the later emergence of aggressive disease. The discovery offers a glimpse of a future in which the body's own chemistry is read as an early record, though the signals remain faint and far from the clinic.
A blood sample drawn years ago, long before anyone suspected illness, may hold a hint of the prostate cancer a man would later develop. Researchers at the Oxford Population Health Centre studied stored samples from the European Prospective Investigation into Cancer and Nutrition, comparing 982 men later diagnosed with prostate cancer against 1,573 randomly chosen participants. Across more than 6,000 proteins measured in each sample, and over roughly 16 years of follow-up, they found seven proteins tied to aggressive disease.
One protein, GZMK, made by immune cells that help destroy abnormal cells, was linked to cancers diagnosed more than 15 years after sampling. The authors suggest immune activity may be holding the disease in check long before it becomes detectable, though this remains an interpretation rather than a proven mechanism. ANKRD1 stood out for its consistent link to severe variants, including metastatic and fatal cases. Other signals pointed to how cancer cells interact with surrounding tissue and to the growth of new blood vessels, while proteins from the ERBB3, KRAS and NRAS genes, already known to matter in prostate cancer, were tied to aggressive disease about a decade on.
Partial comparisons with other large population studies and genetic evidence lend some outside support. Yet the proteins are not ready for clinical use. Most associations are moderate in strength, and whether measuring them would truly sharpen risk assessment is still unknown. That question awaits further study, and its answer will determine whether any of these seven proteins ever reaches a doctor's office.
Blood drawn from a man years ago, long before anyone suspected anything was wrong, turns out to carry hints about the cancer he might later develop. That is the premise of a new study from the Oxford Population Health Centre, which found seven proteins in stored blood whose levels were associated with a future risk of aggressive prostate cancer.
The researchers worked with samples from the European Prospective Investigation into Cancer and Nutrition, known as EPIC. They looked at blood from 982 men who were later diagnosed with prostate cancer, and compared it with a randomly selected group of 1,573 participants from the same study. In all, they measured more than 6,000 proteins in each sample, and followed the participants for about 16 years.
The first finding concerned timing. Twelve proteins were associated with prostate cancer diagnosed more than 15 years after the blood was collected. One of them was GZMK, a protein made by immune cells that helps recognize and destroy abnormal cells. The authors assessed that this could point to immune processes holding the disease in check long before it becomes detectable. That is their interpretation, not a demonstrated mechanism.
Separately, the team singled out seven proteins tied to aggressive forms of the disease. ANKRD1 stood out: it was consistently associated with several severe variants, including metastatic or fatal cases. Other findings pointed to the ways cancer cells interact with surrounding tissue and to the formation of new blood vessels.
The analysis also picked up associations with proteins produced by the ERBB3, KRAS and NRAS genes, which are already known to play a role in prostate cancer. These were linked in particular to aggressive disease diagnosed roughly ten years after sampling. The authors stressed that this does not mean cancer was already present when the blood was taken.
The results were partly compared against data from other large population studies and against genetic evidence, which offers some outside support for the findings.
But the proteins are not ready to be used as clinical tests. Most of the associations were moderate in strength, and it has yet to be shown whether measuring these proteins would improve the assessment of risk for clinically significant cancer. That question is for further studies, and it will decide whether any of the seven ever reach a doctor's office.
Citations marquantes
The associations do not mean cancer was already present when the blood samples were collected.— Study authors, Oxford Population Health Centre
Envie de l'histoire complète ?
Lire l'original sur UA.NEWS ↗
Health & Medicine